Veru Inc. (VERU) Stock Price

VERUStock

$2.71−28.06%52W

Market Cap$46.21M

P/E—

PEG Ratio3.60

Div yield—

Beta-1.20

VERU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-4.22%

Price vs S&P 500 (4W)13.09%

PEG Ratio3.60

VGM Score61.07

Book Value / Share (Quarterly)$2.17

P/TBV (Annual)3.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.92%

Cash Flow / Share (Quarterly)$-1.62

Price vs S&P 500 (YTD)9.07%

Gross Margin (TTM)34.66%

Net Profit Margin (TTM)-223.86%

EPS (TTM)$-0.78

10-Day Avg Trading Volume0.18M

EPS Excl Extra (TTM)$-0.78

Revenue Growth (5Y)-11.89%

EPS (Annual)$-2.80

ROI (Annual)-89.59%

Gross Margin (Annual)34.67%

Net Profit Margin (5Y Avg)-208.17%

Cash / Share (Quarterly)$1.92

Revenue Growth QoQ (YoY)72.36%

ROA (Last FY)-62.57%

Revenue Growth TTM (YoY)3.62%

EBITD / Share (TTM)$-1.04

ROE (5Y Avg)-150.44%

Operating Margin (TTM)-218.61%

Cash Flow / Share (Annual)$-2.05

P/B Ratio1.28x

P/B Ratio (Quarterly)1.02x

Net Income / Employee (Annual)$-1,890,100

EV / Revenue (TTM)0.99x

Net Interest Coverage (TTM)-42.80x

ROA (TTM)-37.76%

EV / EBITDA (TTM)1.27x

EPS Incl Extra (Annual)$-2.80

Current Ratio (Annual)2.43x

Quick Ratio (Quarterly)5.71x

3-Month Avg Trading Volume1.42M

52-Week Price Return-28.06%

Revenue / Employee (TTM)$844,300

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)2.63x

Asset Turnover (Annual)0.28x

52-Week High$7.33

Operating Margin (5Y Avg)-203.80%

EPS Excl Extra (Annual)$-2.80

CapEx CAGR (5Y)-60.34%

Tangible BV CAGR (5Y)21.71%

26-Week Price Return7.02%

Quick Ratio (Annual)2.35x

13-Week Price Return16.67%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.19x

Enterprise Value$16.76M

Revenue / Share Growth (5Y)20.05%

Asset Turnover (TTM)0.24x

Book Value / Share Growth (5Y)23.78%

Revenue / Employee (Annual)$844,300

Inventory Turnover (Annual)2.04x

Pretax Margin (Annual)-219.56%

Cash / Share (Annual)$1.25

3-Month Return Std Dev192.40%

Gross Margin (5Y Avg)61.87%

Net Income / Employee (TTM)$-697,700

ROE (Last FY)-116.97%

Net Interest Coverage (Annual)-42.83x

EPS Basic Excl Extra (Annual)$-2.80

P/FCF (TTM)11.17x

Receivables Turnover (TTM)3.99x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.78

Receivables Turnover (Annual)3.99x

ROI (TTM)-52.86%

P/S Ratio (TTM)2.63x

Pretax Margin (5Y Avg)-208.12%

Revenue / Share (Annual)$1.25

Tangible BV / Share (Annual)$2.21

Price vs S&P 500 (52W)-46.37%

Year-to-Date Return21.03%

5-Day Price Return0.00%

EPS Normalized (Annual)$-2.80

ROA (5Y Avg)-68.61%

Net Profit Margin (Annual)-223.86%

Month-to-Date Return15.63%

Cash Flow / Share (TTM)$-1.49

EBITD / Share (Annual)$-2.72

Operating Margin (Annual)-218.61%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-107.33%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.78

P/TBV (Quarterly)3.48x

P/B Ratio (Annual)3.04x

Inventory Turnover (TTM)2.04x

Pretax Margin (TTM)-219.56%

Book Value / Share (Annual)$1.25

Price vs S&P 500 (13W)13.87%

Beta-1.20x

P/FCF (Annual)52.19x

Revenue / Share (TTM)$1.15

ROE (TTM)-52.86%

52-Week Low$2.05

vGradeB

gGradeC

mGradeC

vgmGradeB

VERU Earnings Surprise History

Q2 25-0.53est. -0.50

Q3 250.09est. -0.39

Q4 25-0.26est. -0.47

Q1 26-0.13est. -0.28

Q2 26-0.30est. -0.32

VERU Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
VERUVeru Inc.	B	C	C	$2.71
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Veru Inc.

Veru is a late-stage biopharmaceutical developing therapies for cardiometabolic and inflammatory diseases. Enobosarm, a selective androgen receptor modulator, is in Phase 2b development for obesity to enhance fat loss selectivity when combined with GLP-1 RA drugs. Sabizabulin, an oral microtubule disruptor, is advancing to Phase 2 trials for atherosclerotic cardiovascular disease to reduce inflammation and high-sensitivity CRP levels.